Affimed is supported by a strong syndicate of renowned international life sciences investors that in September 2012 further financed our activities with € 15.5 million.
Affimed has raised a total of € 68.5 million in four VC financing rounds. In 2007/2008 the company raised € 30 million in a Series B round with the lead investors Orbimed, BioMedInvest, Aeris Capital, Life Science Partners and Novo Nordisk A/S. Affimed increased its equity funding by an additional € 15 million in a Series C led by the existing investors in April 2010. Recently, in September 2012 Affimed closed successfully a Series D financing round of € 15.5 million. In addition, the company has successfully applied for grants totaling to € 6.0 million.
Our top tier life science VC syndicate include
aeris CAPITAL (Switzerland)
aeris CAPITAL is a private Swiss investment office, advising a high net worth individual and his foundation, one of the largest German charitable foundations. aeris CAPITAL is active in all asset classes, globally. Operating from a sustainable asset base, with a long-term investment horizon, aeris strives to achieve the highest quality standards in all its investment activities, while delivering superior, risk-adjusted returns.
BioMedInvest AG is a healthcare-dedicated venture capital fund based in Switzerland, providing private equity financing to early to mid-stage companies in Switzerland and neighbouring regions (Alpine Rim).
World’s largest healthcare-dedicated investment firm — with approximately $5 billion in assets under management. OrbiMed’s investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies, from private start-ups to large multinational companies.
Life Sciences Partners
One of the world’s largest specialized healthcare and biotechnology investment firms. With a history dating back to the late eighties, LSP has grown into a global firm with offices in Amsterdam, Munich and Boston.
Novo Nordisk A/S
Novo Nordisk A/S is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk A/S has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy.
Do you have any questions? Would you like to learn more about Affimed? Please contact our CFO, Dr. Florian Fischer.
Dr. Florian Fischer - Chief Financial Officer - Affimed
Phonework: + 49 6221 65307 - 0